Shares of Zafgen Inc. (ZFGN) slumped more than 25% in after-hours Monday, following the Company's decision to suspend plans to file an investigational new drug application for ZGN-1258, a candidate for rare metabolic disorders including Prader-Willi syndrome.
from RTT - Biotech https://ift.tt/2JaqsH4
via IFTTT
No comments:
Post a Comment